BC Week In Review | May 25, 2009
Clinical News

CEA-expressing VRP vaccine: Completed Phase I/II enrollment

AlphaVax completed enrollment of 24 patients in an open-label, dose-escalation, U.S. Phase I/ll trial evaluating the intramuscular vaccine given every 3 weeks for a minimum of 4 immunizations, with additional doses given every 3 months...
Items per page:
1 - 1 of 1